Several studies in the literature have demonstrated the potential chemo-preventive effect of oral contraceptives in reducing ovarian cancer risk among BRCA1 and BRCA2 mutation carriers [23,24]. This evidence concerns the gene BRCA1 and ovarian carcinoma.